CDTX - Cidara Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5300
+0.0600 (+2.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.4700
Open2.4900
Bid2.01 x 1400
Ask3.50 x 800
Day's Range2.4800 - 2.6199
52 Week Range1.9400 - 8.5500
Volume123,285
Avg. Volume119,581
Market Cap70.211M
Beta (3Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateMay 12, 2017 - May 15, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.54
Trade prices are not sourced from all markets
  • Business Wire12 days ago

    Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) to be held in Houston, Texas from February 20-24, 2019. “The TCT meeting is an important venue for Cidara to share data that demonstrate the potential advantages of rezafungin for the prevention of invasive fungal infections in blood and marrow transplant patients,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. Invasive fungal infections (IFIs) are a leading cause of morbidity and mortality among immunocompromised patients, particularly those undergoing blood and marrow transplantation.

  • PR Newswirelast month

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • How Does Investing In Cidara Therapeutics, Inc. (NASDAQ:CDTX) Impact The Volatility Of Your Portfolio?
    Simply Wall St.2 months ago

    How Does Investing In Cidara Therapeutics, Inc. (NASDAQ:CDTX) Impact The Volatility Of Your Portfolio?

    If you're interested in Cidara Therapeutics, Inc. (NASDAQ:CDTX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • Business Wire2 months ago

    Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien, J.D., as general counsel and secretary. “We are extremely pleased to welcome Jamie and Jessica to our executive management team.

  • Cidara Therapeutics (CDTX) Enters Oversold Territory
    Zacks3 months ago

    Cidara Therapeutics (CDTX) Enters Oversold Territory

    Cidara Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Business Wire3 months ago

    Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting. The 2018 ASH Meeting will be held December 1-4 in San Diego. The rezafungin ASH abstract (2071), titled “Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients," will be presented in a poster session on Saturday, December 1.

  • Business Wire3 months ago

    Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year. Cidara ranked among the top 15 small companies, and the number one ranked biotech in the small company category, in the San Diego Metro Area. “We are once again honored to be recognized as a top workplace by our employees, whose feedback reflects our commitment to nurturing a positive work environment where we are true to our values and advocate for integrity, collaboration, urgency, accountability and courage,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

  • Associated Press3 months ago

    Cidara Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 49 cents. In the final minutes of trading on Thursday, the company's shares hit $4.13. A year ago, they were trading at $7.95. _____ ...

  • Business Wire4 months ago

    Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress

    Cidara Therapeutics, Inc. , a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance Congress taking place October 25-26, 2018 in Washington, DC.

  • Business Wire4 months ago

    Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Hot Topics in Infectious Diseases (HTIDE) is a bi-annual conference which convenes more than 400 delegates from all over the world to discuss topics on novel approaches to diagnosis and treatment of infectious diseases.

  • Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
    Business Wire4 months ago

    Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company’s Phase 2 STRIVE trial of rezafungin at IDWeek 2018, taking place in San Francisco from October 3-7. The STRIVE trial successfully achieved its primary endpoints, demonstrating the efficacy and safety of once-weekly dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis.

  • Business Wire5 months ago

    Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. “Difficult-to-treat, invasive Candida infections are associated with a high mortality and affect the most vulnerable patients.

  • Shareholders Should Check If Insiders Own Shares In Cidara Therapeutics Inc (NASDAQ:CDTX)
    Simply Wall St.5 months ago

    Shareholders Should Check If Insiders Own Shares In Cidara Therapeutics Inc (NASDAQ:CDTX)

    The big shareholder groups in Cidara Therapeutics Inc (NASDAQ:CDTX) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders ownRead More...

  • Business Wire5 months ago

    FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the company’s prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. Specifically, the QIDP designation is for the development of rezafungin for the prevention of invasive fungal infections in adults undergoing allogeneic bone marrow transplantation.

  • Business Wire5 months ago

    Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of industry leader David Gollaher, Ph.D., to the company’s Board of Directors. “With more than 30 years of experience in the biopharma and healthcare industry, Dr. Gollaher is an outstanding addition to our Board,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

  • Business Wire5 months ago

    Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data demonstrating the broad clinical utility and potency of the company’s lead antifungal product candidate, rezafungin, will be presented at IDWeek 2018, being held October 3-7 in San Francisco. Four separate IDWeek presentations will focus on rezafungin, the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections, and will include the efficacy and safety results from Cidara’s Phase 2 STRIVE trial.

  • Business Wire5 months ago

    Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data highlighting the company’s innovative Cloudbreak™ immunotherapy discovery platform will be presented at two upcoming conferences. Cloudbreak is a novel platform that pairs potent antimicrobials with agents that redirect the immune system to destroy fungal, bacterial and viral pathogens.

  • Associated Press6 months ago

    Cidara Therapeutics: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of $1.13 per share. Losses, adjusted for non-recurring costs, came to 69 cents per share. In the final minutes of trading on Wednesday, the company's shares ...

  • Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zacks7 months ago

    Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Cidara Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Business Wire8 months ago

    Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Dr. Taylor Sandison, chief medical officer, will present clinical efficacy and safety data for the company’s lead antifungal rezafungin for the treatment and prevention of invasive fungal infections at two upcoming, global infectious disease conferences. Abstracts highlighting rezafungin data have been accepted at The 20th International Immunocompromised Host Society (ICHS) Symposium in Athens, Greece, taking place June 17-19, 2018, and The International Society for Human and Animal Mycology (ISHAM) Congress in Amsterdam, taking place in The Netherlands, June 30-July 4, 2018.

  • PR Newswire8 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...